FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology, and can be applied as adaptation potential assessment method. Patient examination is performed, the following indicators are determined: lymphocyte index (LI), adaptation index (total index of non-specific resistance, TINR), immunoreactivity index (IRI). Further adaptation coefficients (K) for each indicator are defined on the basis of obtained data. Namely, in LI system K is (-1.3) for marker up to 0.4, (-1.2) for marker within 0.41-0.5, (-1.1) for marker within 0.51-0.6, (+1) for marker within 0.61-0.7, (+1) for marker within 0.71-0.8, (+1.2) for marker within 0.81-1.0, (+1.3) for marker over 1.0. In TINR system K is (-1.3) for marker up to 0.3, (-1.2) for marker within 0.31-0.5, (-1.1) for marker within 0.51-0.7, (+1) for marker within 0.71-0.9, (+1.1) for marker within 0.91-1.1, (+1.2) for marker within 1.11-1.3, (+1.3) for marker over 1.3. In IRI system K is (-1.3) for marker up to 3.0, (-1.2) for marker within 3.01-5.0, (-1.1) for marker within 5.01-7.0, (+1) for marker within 7.01-9.0, (+1.1) for marker within 9.01-11.0, (+1.2) for marker within 11.01-13.0, (+1.3) for marker over 13.0. Total adaptation potential indicator (TAPI) for breast cancer patients is obtained by aggregation of K of all indicators. For TAPI under 1 adaptation potential is considered low, for TAPI within 1 to 3 adaptation potential is considered satisfactory, for TAPI over 3 adaptation potential is considered high.
EFFECT: possible assessment of adaptation potential for breast cancer patients at various treatment stages for assessment of treatment efficiency and further forecast using standard paraclinic tests.
2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF ESTIMATING ADEQUACY OF PHYSICAL EXERCISE FOR GOING IN FOR SPORT TEENAGERS | 2011 |
|
RU2468753C1 |
METHOD FOR EVALUATING IMMUNE FUNCTIONAL BODY RESERVE | 2014 |
|
RU2557985C1 |
METHOD FOR PREDICTION OF BREAST CANCER STAGES | 2008 |
|
RU2393474C1 |
RECURRENT AND METASTASING CERVICAL CARCINOMA TREATMENT EFFECTIVENESS PREDICTION METHOD | 2007 |
|
RU2353928C1 |
METHOD FOR PREDICTING DEVELOPMENT OF POSTOPERATIVE COMPLICATIONS IN PANCREATODUODENAL RESECTION IN PATIENTS WITH CANCER OF ORGANS OF THE BILIARY PANCREATODUODENAL ZONE | 2017 |
|
RU2650984C1 |
METHOD OF CORRECTION OF ESTROGEN DEFICIENCY CONDITIONS IN PATIENTS WITH PREMENOPAUSAL PERIOD WITH DIAGNOSIS OF HR-POSITIVE BREAST CANCER DURING FORMATION OF SUSTAINABLE NEUROTIC AND SOMATIC SYMPTOMS IN FORM OF ACUTE STRESS AND MANIFESTATIONS OF POSTOVARIECTOMY SYNDROME | 2017 |
|
RU2675773C1 |
PREPARATION OF ADAPTOGENIC ACTION AND METHOD FOR PREPARING PATIENTS WITH MAMMARY CANCER FOR CARRYING OUT SPECIFIC ANTI-TUMOR TREATMENT AT APPLYING POLYCHEMOTHERAPY | 2004 |
|
RU2304445C2 |
METHOD FOR PREDICTION OF HAEMATOGENIC METASTASIS IN BREAST CANCER PATIENTS AFTER ANTICANCER TREATMENT | 2010 |
|
RU2436099C1 |
MEANS FOR BREAST CANCER PREDICTION | 2016 |
|
RU2631940C1 |
METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
Authors
Dates
2010-06-27—Published
2008-10-21—Filed